The Anti-cancer Drug Design is a research journal published by the Cognizant Communication Corporation. The P-ISSN of this journal is 2669536.
Also, please check the following important details about anti-cancer drug design: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.
According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.
| Journal Title: | Anti-Cancer Drug Design |
| Publisher: | Cognizant Communication Corporation |
| P-ISSN: | 2669536 |
| Open Access: | |
| Status: | Inactive |
| Scopus Coverage: | 1985-2001 |
The anti-cancer drug design is indexed in:
An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.
The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).
The publication time may vary depending on factors such as the complexity of the research and the current workload of the editorial team. Journals typically request reviewers to submit their reviews within 3-4 weeks. However, some journals lack mechanisms to enforce this deadline, making it difficult to predict the duration of the peer review process.
The review time also depends upon the quality of the research paper.
Visit to the official website of the journal/ conference to check the details about call for papers.
If your research is related to the scope of the journal, then visit the official website of anti-cancer drug design and send your manuscript.